Screener
Enliven Therapeutics ELVN Shares (Diluted)
Shares (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Enliven Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding.
The source filing: Enliven Therapeutics’s 10-Q, filed May 7, 2026. Open the filing →
- Filed
- May 7, 2026, 4:17 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-211982
FAQ
- What is Enliven Therapeutics's shares (diluted)?
- Enliven Therapeutics (ELVN) reported shares (diluted) of 62.8M in Q1 2026.
- How has Enliven Therapeutics's shares (diluted) changed year-over-year?
- Enliven Therapeutics's shares (diluted) increased by 25.5% year-over-year, from 50.1M to 62.8M.
- What is the long-term trend for Enliven Therapeutics's shares (diluted)?
- Over 4 years (2021 to 2025), Enliven Therapeutics's shares (diluted) has grown at a 31.2% compound annual growth rate (CAGR), from 74.7M to 220.9M.
- What does shares (diluted) mean?
- The weighted-average shares outstanding plus all potentially dilutive shares from stock options, RSUs, convertible securities, and warrants, using the treasury stock method.
Ask your AI about Enliven Therapeutics's shares (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude